Target Name: NPSR1-AS1
NCBI ID: G404744
Review Report on NPSR1-AS1 Target / Biomarker Content of Review Report on NPSR1-AS1 Target / Biomarker
NPSR1-AS1
Other Name(s): AAA1 | NPSR1 antisense RNA 1, transcript variant 3 | NPSR1 antisense RNA 1, transcript variant 1 | NPSR1 antisense RNA 1

NPSR1-AS1: A Promising Drug Target for Cancer Treatment

NPSR1-AS1 (AAA1) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression patterns make it an attractive target for researchers to study.

NPSR1-AS1 is a RNA molecule that is located in the nucleus of the cell. It is composed of four exons, which are the parts of the molecule that code for the amino acids that make up the protein. The first exon contains the sequence NPSR1 , while the second exon contains the sequence AS1. The remaining two exons contain the sequences that are unique to NPSR1-AS1.

The structure of NPSR1-AS1 is unique as well. It has a specific five-base pair repeat sequence, which is repeated multiple times in different regions of the molecule. This repeat sequence is the only known sequence that is specific to NPSR1-AS1. The repetitive nature of the sequence makes it an attractive target for drugs that can inhibit its activity.

In addition to its unique structure, NPSR1-AS1 has also been shown to have unique expression patterns. Studies have shown that NPSR1-AS1 is highly expressed in a variety of tissues and cells, including cancer cells. This makes it an attractive target for drugs that can reduce its expression.

The potential benefits of targeting NPSR1-AS1 are numerous. If successful, these drugs have the potential to treat a wide range of diseases, including cancer. By inhibiting the activity of NPSR1-AS1, these drugs can prevent cancer cells from multiplying and spreading. In addition, targeting NPSR1-AS1 has the potential to be a more targeted and effective treatment than traditional cancer treatments.

Targeting NPSR1-AS1 has the potential to be especially effective in certain types of cancer. For example, studies have shown that NPSR1-AS1 is highly expressed in breast cancer cells. This makes it an attractive target for drugs that can inhibit its activity in these cells. In addition, NPSR1-AS1 has also been shown to be highly expressed in other types of cancer cells, including lung cancer and ovarian cancer. This makes it a promising target for drugs that can treat these cancers as well.

The development of NPSR1-AS1 as a drug target or biomarker is still in its early stages, but it holds great promise for the treatment of a wide range of diseases. Further research is needed to fully understand the potential of NPSR1-AS1 as a drug target and to develop effective treatments.

In conclusion, NPSR1-AS1 is a unique and promising drug target or biomarker with potential for the treatment of a wide range of diseases. Its structure and expression patterns make it an attractive target for researchers to study, and its unique properties give it a distinct advantage over other potential drug targets. Further research is needed to fully understand the potential of NPSR1-AS1 and to develop effective treatments.

Protein Name: NPSR1 Antisense RNA 1

The "NPSR1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPSR1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3 | NSDHL | NSF | NSFL1C | NSFP1 | NSG1 | NSG2 | NSL complex | NSL1 | NSMAF | NSMCE1